Tivantinib in Treating Younger Patients With Relapsed or Refractory Solid Tumors

Summary

This phase I trial studies the side effects and best dose of tivantinib in treating younger patients with solid tumors that have returned after a period of improvement or have not responded to treatment. Tivantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Timeline

Start

2012-10

Primary completion

2015-05

Completion

2015-05

Drugs

Indications